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EFECTO INMUNOMODULADOR DE LA FIBRA,
PROBIÓTICOS Y SIMBIÓTICOS EN LAS
DIFERENTES ETAPAS DE LA VIDA
Resumen
Las enfermedades crónicas relacionadas con el estilo
de vida frecuentemente están asociadas con una altera-
ción del sistema inmunológico. En este sentido, ya que la
dieta es capaz de modular la resistencia a infecciones y
procesos inflamatorios, el consumo de fibra y probióticos
parece ser una herramienta prometedora en la modula-
ción del sistema inmune en diferentes poblaciones. Los
efectos saludables de la fibra dietética y los probióticos
han sido documentados en numerosos estudios epidemio-
lógicos y de intervención, especialmente sus efectos bene-
ficiosos sobre la microbiota del intestino con implicacio-
nes clínicas importantes en la prevención y/o tratamiento
de enfermedades infecciosas e inflamatorias. Los meca-
nismos incluyen la modulación de las propiedades funcio-
nales de la microbiota, células epiteliales, dendríticas e
inmunológicas. Se han estudiado en profundidad cómo
los prebióticos afectan a la composición de la microbiota
del intestino, estimulando beneficiosamente a otros
comensales además de las bacterias acido lácticas,
abriendo así una futura línea de investigación con nuevas
cepas de probióticos y combinaciones de sinbióticos. Por
otro lado, están bien establecidos los cambios en la fisiolo-
gía del intestino, microbiota y respuesta inmune atribui-
dos al envejecimiento están bien establecidos. Además,
las agresiones externas en los primeros días de vida, la ali-
mentación con formulas infantiles, el tratamiento con
probióticos, las enfermedades gastrointestinales y el
estrés, también alteran el desarrollo y equilibrio de la
microbiota intestinal. Por todo ello, esta revisión ofrece
una visión actual sobre los aspectos mas relevantes del
efecto de la fibra, probióticos y simbióticos sobre el sis-
tema inmune en las diferentes etapas de la vida.
(Nutr Hosp. 2010;25:341-349)
DOI:10.3305/nh.2010.25.3.4517
Palabras clave: Inmunomodulación. Fibra. Probióticos.
Abstract
Chronic diseases associated to modern lifestyle habits
are usually related to immune system malfunction. In this
context, since diet is very well-known to modulate host
resistance to infectious and inflammatory processes, the
consumption of fibre and probiotics seems to be a promis-
ing nutritional tool for immune system modulation in dif-
ferent populations. Health effects of dietary fibres and pro-
biotics have been extensively documented in numerous
epidemiological and intervention studies, especially their
beneficial effect on intestinal microbiota with important
clinical implications in the prevention and/or treatment of
infectious and inflammatory diseases. Mechanisms may
include modulation of the functional properties of the
microbiota, epithelial cells, dendritic cells and immune cell
types. Prebiotics have been extensively reported to affect
the composition of the gut microbiota, stimulating directly
or indirectly putative beneficial gut commensals other than
lactic acid bacteria, opening promising areas of research for
the discovery of new probiotic strains and synbiotic combi-
nations. Age-related changes in gut physiology, microbiota
and mucosal immune response are well established. More-
over, exposure to different challenges during life such as
early encounter of environmental insults in the newborn,
infant formula feeding, antibiotic treatment, gastrointesti-
nal diseases and stress, also interferes with the normal
development and balance of the healthy gut microbiota.
Therefore, the current short review gives an overview of
today’s main aspects of the effect of fibres, probiotics and
synbiotics on the immune system in different life-stages. 
(Nutr Hosp. 2010;25:341-349)
DOI:10.3305/nh.2010.25.3.4517
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Developed societies are facing up to a progressive
increase on immune-mediated and gut-related health
problems, such as allergies and auto-immune and
inflammatory diseases.1 Recent compelling evidence
has suggested that emerging nutritional strategies may
contribute to decrease these host-related diseases
manipulating the microbiota by diet.2,3 In this context,
the increased use of prebiotic fibres and probiotics has
become a major area of interest within the nutrition
community1 and seems to be a promising nutritional
tool to modulate the immune system in different popu-
lations. These specific nutrients/ingredients are
included into several functional foods that may
improve the functions of both the immune system and
the gut physiology as well as metabolic functions.4-6
Mechanisms contributing to altered in vivo immune
function induced by functional foods may include
modulation of the microflora itself, improved barrier
function and direct effects of bacteria on different
epithelial and immune cell types (monocytes/
macrophages, B cells, T cells and NK cells).3 The
increasing incidence of allergies may be explained by a
dysregulation in the T helper (Th1/Th2) balance linked
to the modern hygienic lifestyle, but this does not
explain the increased incidence of other disorders such
as inflammatory bowel diseases, which are all primar-
ily driven by Th1 cells.7-9 In this respect some animal
studies have suggested that induction of regulatory T
cells by certain microorganisms can prevent or allevi-
ate such diseases.10 In any case, despite the positive
clinical effects on the prevention and treatment of sev-
eral immune-related diseases, the mechanisms of this
type of functional foods are still not completely under-
stood.11
Age-related physiological changes
Although relatively little work has been done to
describe the gastrointestinal changes associated with
normal aging in humans, age-related changes in gut
physiology, microflora and mucosal immune response
are well established.12 Exposure to different challenges
during life such as early encounter of environmental
insults in the newborn, infant formula feeding, antibi-
otic treatment, gastrointestinal diseases and stress,
interfere with the normal development and balance of
the healthy gut microflora.4
The pattern of intestinal microflora undergoes major
ecologic modifications in the early stages of life.13
Some authors have suggested that adequate establish-
ment of the intestinal flora after birth plays a crucial
role in the development of the innate and adaptive
immune system.14 In fact, infants are highly susceptible
to infection during early life, which, in large part, is the
result of delayed development of the immune function
and changes in the composition and number of gut flora
after weaning.15-17 The colonization of the human intes-
tine begins at birth and the composition of the intestinal
microbiota is influenced by diet composition.13 Breast
feeding constitutes one route for oral delivery of
microbes and antigens. In addition, it has been reported
that human milk provides molecules with antimicro-
bial activity18 as well as probiotic bacteria such as Lac-
tobacillus gasseri and Lactobacillus fermentum.19
On the other hand, the activity of the immune system
and the development of mucosal immune responses to
new antigens decline with age.4,20 The number of fac-
tors affecting the idiosyncratic immune characteristics
of the individual, such as environmental insults, alter-
ation of the microflora, along with the risk of inflam-
matory diseases, increase with age.4,21 For example,
numbers of bifidobacteria in the gut decrease markedly
after 55-60 years of age.22 Therefore, prebiotics and
probiotics may have a particular interest in this high-
risk group, even preventing immune senescence and
several age-related diseases.
Prebiotic and probiotic immune protection 
in infants and children
Prebiotics target indigenous beneficial bacteria
already established in the gut and have become rele-
vant in infant nutrition, as formula-fed infants usually
have lower numbers of bifidobacteria compared to the
breastfed infants.23-25 Taking breast-feeding as the nat-
ural example of infant nutrition, the prebiotics
approach should be considered as a physiological
approach to influence intestinal microbiota early in
life. In this regard, Bruzzese et al.13 suggested that the
addition of non digestible oligosaccharides and inulin
to infant food may exert a comparable effect to human
milk. Moreover, prebiotics can simulate the bifido-
genic effects of breast milk oligosaccharides and have
been shown to exert long-term effects (up to two years)
for protecting against infection, lowering the incidence
of allergy and also exerting positive consequences for
the postnatal development of the immune system.26,27
The prebiotic fibres inulin and oligosaccharides
have been extensively studied in infants and children.
The addition of the inulin/galactooligosaccharides
(GOS) mixture in weaning foods of 4- to 6-month-old
infants in a daily dose of 4,5 g during 6 wk succeeded in
increasing of the faecal percentage of Bifidobacteria
population (form 43 to 57%) of the fecal flora.28 Other
intervention study in infants receiving an inulin/GOS
mixture during 12 months, significantly decreased the
episodes of gastrointestinal and respiratory tract infec-
tions,13 also enhancing faecal immunoglobulin (Ig) A
levels.29 Moreover, inulin and oligofructose have also
been reported as promoting positive effects as indi-
cated by a lower incidence of febrile episodes in
infants.30 Regarding oligosaccharides alone, a benefi-
cial effect on the immune system of preterm infants due
to the specific conditions in the luminal part of the
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developing gut wall, have also been suggested by
Westerbeek et al.31 after administration of the combina-
tion of neutral oligosaccharides with acidic oligosac-
charides (maximal dose of 1.5 g/kg/day added to breast
milk or preterm formula).
As aforementioned, a well-proven effect of prebi-
otics has been described in infants but children and
adolescents have so far inspired few clinical studies
testing the effects of prebiotics on immunity30 and fur-
ther studies are needed in this direction.
Probiotics have been more deeply studied in infancy
and childhood, particularly in regard to the prevention
of allergic diseases and reinforcement of the gut
defence, stimulating a low-grade inflammation by acti-
vating the innate immune system and further produc-
tion of IL-10.1,32 Lactobacillus rhamnosus GG (LGG)
has extensively been studied on the prevention and
treatment of acute infantile diarrhoea, antibiotic associ-
ated diarrhoea and atopic dermatitis with very interest-
ing results.1,4,33,34 Bifidobacteria (i.e. B. infantis and B.
bifidum) in combination with different strains of Lacto-
bacillus spp. have been documented to be useful in
diarrhoea prevention and treatment35. Lactobacillus
coryniformis CECT5711 and Lactobacillus gasseri
CECT5714 have also shown beneficial effects on
intestinal flora of healthy children.36
The inclusion of yoghurt containing probiotics (375
g/day) over 10 weeks in a group of adolescents with
anorexia nervosa (AN), showed a positive immunomodu-
lator effect [higher CD4/CD8 ratio and increased IFN-γ
production by stimulated peripheral blood mononu-
clear cells (PBMCs)],37 suggesting the potential impact
of probiotics on this malnourished population. 
The synbiotic formed by L. rhamnosus LCR35 plus
a specific prebiotic preparation containing lactose (that
LCR35 is able to hydrolyse) and potato starch used in
the fermentation broth and the prebiotic alone com-
posed of the same fermentation broth seem to be able to
significantly improve the manifestations of atopic der-
matitis in children aged 2 years and over.38 Moreover,
the treatment of the intestinal infections among chil-
dren with a synbiotic product (containing B. bifidum,
B. longum, L. casei strains and fibre) reduced the dura-
tion of the diarrhoea syndrome and provided a com-
plete recovery of the intestinal microbiota balance.39 A
positive effect on intestinal flora and systemic immune
response (counts and activity of lymphocytes) in chil-
dren with short bowel syndrome has been pointed out
after 1 year of synbiotic therapy including Bifidobac-
terium breve, Lactobacillus casei and GOS.40 Other
authors have suggested that in ill children receiving
antibiotics, synbiotics may confer additional benefits
by increasing bifidobacteria levels.41
Regarding long-term safety in infants, some aspects
remain unclear. While feeding synbiotics to newborn
infants has been suggested to be safe and to increase
resistance to respiratory infections during the first 2
years of life,42 the real evidence about their clinical ben-
efits and safety of prenatal and postnatal probiotic
treatments still remains unclear.43 Hence, further
research seems to be needed in this direction. 
Prebiotic and probiotic immune protection 
in adults and elderly
The modulation of the intestinal microbiota by dietary
fibre has been established to serve as a useful adjunct in
the treatment of gastrointestinal and inflammatory dis-
ease in adults.44-47 Recent evidence even suggests that
inhibition of inflammatory processes may be an impor-
tant mediator in the association between dietary fibre
consumption and cardiovascular diseases (CVD). In
fact, cross-sectional and randomized crossover interven-
tion trials have demonstrated an association between
dietary fibre and clinical inflammation biomarkers, such
as C-reactive protein (CRP).45,49
In experimental models, prebiotics such as inulin
and oligofructose have been associated with reduced
mucosal inflammation and may offer an opportunity to
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Fig. 1.—Main effects of fibres,
probio tics and synbiotics on the im-


















– –Adults and elderly
Synbiotics Probiotics
prevent inflammatory bowel disease and other mucosal
inflammatory disorders.50 Other health effects of prebi-
otics (prevention of diarrhoea, modulation of the
intestinal microbiota metabolism, cancer prevention,
positive effects on lipid metabolism, stimulation of
mineral adsorption) are indirect, i.e. mediated by the
intestinal microbiota, and therefore less-well proven.51
On the other hand, recent studies have shown the
potentially extensive impact of prebiotics on gut
microbiota composition,26,52 stimulating directly or
indirectly putative beneficial gut commensals other
than lactic acid bacteria, opening exciting areas of
research for the discovery of new probiotic strains and
synbiotic combinations.53
Probiotics have been suggested to be capable to
modulate the metabolism of short chain fatty acids,
amino acids and plasma lipoproteins, demonstrating
the diversity of synbiotic co-metabolic connections
between the gut microbiota and the host.54 The preven-
tion and/or treatment of infectious and antibiotic-asso-
ciated diarrhoea, allergic diseases, inflammatory
bowel disorders and prevention of respiratory tract
infections by probiotics, have been documented in
adults.51,55,56
Regular, long-term intake of various synbiotics has
been shown to improve adult health by reducing the
incidence and severity of respiratory diseases during
the cold season,57 suggesting a synergistic effect of
both probiotic and prebiotic ingredients. Synbiotics
have also been suggested to alter the composition of the
colonic microbiota, reduce inflammatory processes in
the gut mucosa, and have the potential to induce dis-
ease remission in inflammatory bowel diseases.58 In
surgical patients, evidence from the existing random-
ized, controlled studies has shown that some synbiotics
are able to prevent bacterial infections.59 Regarding
aging, prebiotics, probiotics and synbiotics also might
improve gut microbiota and the inflammatory condi-
tion of the elderly.60
Summary
There are numerous studies reporting effects on
immunity with prebiotics, probiotics and synbiotics
(table I). Despite the positive clinical effects on the pre-
vention and treatment of immune-related diseases, the
molecular mechanisms by which probiotics affect the
immune system remain mostly unknown; further
research in this area is needed.11 The identification of
specific strains with anti-allergenic potential and the
question, how food matrix and dietary content interact
with the most efficacious probiotic strains also require
further research.61
Prebiotics have been less extensively studied; how-
ever, they may become an ideal treatment or co-treat-
ment option in inflammatory bowel disease due to their
capacity to increase endogenous lactobacilli and bifi-
dobacteria.62
Since the early immune development in infants and
the markedly declining immune function (immunose-
nescence) in the elderly have extensively been studied,
prebiotic fibres, probiotics and synbiotics may be tar-
geted for these specific age groups. Although the
development of synbiotics to improve prevention
and/or treatment of immune-related diseases have
emerged as a new strategy for nutritionists and other
health professionals, further intervention studies are
needed to prove any added benefits or health effects of
this combination of ingredients and scientific verifica-
tion will be critical to the success of this concept63.
Moreover, further studies to ascertain the mechanisms,
the optimal dose/duration and the long-term safety for
the intervention in different age groups are also
needed.
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